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Nuclear factor-kappa B (NF-κB)Chronic inﬂammation and reduced blood levels of omega-3 fatty acids (n−3) are known characteristics of sickle
cell disease (SCD).The anti-inﬂammatory properties of n−3 fatty acids are well recognized.
Omega-3 treated (n= 24), hydroxyurea (HU) treated (n= 18), and n−3 untreated (n= 21) homozygous SCD
patients (HbSS) and healthy (HbAA) controls (n= 25)matched for age (5–16 years), gender and socioeconomic
status were studied. According to age (5–10) or (11–16) years, two or three capsules containing 277.8 mg
docosahexaenoic (DHA) and 39.0 mg eicosapentaenoic (EPA) or high oleic acid placebo (41%) were assigned
to n−3 treated and n−3 untreated groups, respectively. Hydroxyurea treated group was on dosage more
than 20 mg/kg/day. The effect of supplementation on systemic and blood cell markers of inﬂammation was
investigated.
The n−3 treated group had higher levels of DHA and EPA (p b 0.001) and lower white blood cell count and
monocyte integrin (p b 0.05) compared with the n−3 untreated. No difference was detected between the two
groups regarding C-reactive protein, granulocytes integrin and selectin, plasma tumour necrosis factor-α and
interleukin-10. The n−3 treated group had lowered nuclear factor-kappa B (NF-κB) gene expression compared
to n−3 untreated and HU treated groups (p b 0.05).
This study provides evidence that supplementation with n−3 fatty acids may ameliorate inﬂammation and
blood cell adhesion in patients with SCD.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
The classical paradigm of sickle cell disease (SCD) pathophysiology
has always considered haemoglobin S (HbS) polymerisation and red
cell sickling as the primary causative factor of acute and chronic compli-
cations associated with the disease [1]. Though, recent advances in SCD
research have revealed a more complex pathophysiology of the disease
[2–4]. Indeed, it has been demonstrated that inﬂammation and
increased leukocyte–erythrocyte–endothelial interactions are the
major potential initiating mechanisms of recurrent occlusion of blood
vessels [5,6]. In addition, the therapeutic effect of hydroxyurea, thed Child Foundation, UK• The
chemistry, Faculty of Medicine,
.
hsph.harvard.edu (A.A. Daak).common treatment for SCD, and some emerging experimental treat-
ments is chieﬂy attributed to their anti-inﬂammatory and anti-adhesive
properties [7–10].
The beneﬁcial effects of long-chain omega-3 polyunsaturated fatty
acids (n−3), such as eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), on chronic inﬂammatory disorders arewell recognized [11].
Moreover, studies have revealed that supplementation with omega-3
fatty acids can decrease production of pro-inﬂammatory cytokines and
adhesive molecules [11–13]. Interestingly, research on patients with
SCD invariably found a high n−6/n−3 ratio in blood cells and plasma.
These ﬁndings indicated the important role of fatty acid abnormality in
the chronic inﬂammatory state associated with the disease [14,15]. In
addition, our group and others have shown that supplementing SCD
patients with omega-3 fatty acids corrects cell membrane abnormalities
and confer protection against vaso-occlusive pain episodes, severe
anaemia andoxidative stress [16–19], and improves red blood cellsﬂex-
ibility in mice [20]. However, little is known about the potential anti-
inﬂammatory role of n−3 fatty acids in SCD.
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inﬂammatory effects are not fully understood. Nevertheless, mounting
evidence indicates the importance of nuclear factor-kappa B (NF-κB)
gene [21,22], a key transcription factor involved in the up-regulation
of inﬂammatory cytokines and adhesive molecules genes [23]. There-
fore, we postulated that the observed therapeutic effect of omega-3
fatty acids supplementation on sickle cell disease could partly implicate
suppression of NF-κB gene transcription and adhesivemolecule expres-
sion in patients with SCD.
In this study, we investigated a) whether supplementation with
n−3 DHA and EPA ameliorates systemic markers of inﬂammation and
blood cells adhesion and b) modulates NF-κB gene expression.
2. Methods
2.1. Subjects
This studywas conducted in the context of a single centre, two-arms,
randomised, placebo-controlled, double blinded clinical trial [16].
Steady state homozygous (HbSS) sickle cell patients (who did not expe-
rience painful crisis or other acutemedical condition for at least 1month)
were enrolled in Ibn-Aoaf Paediatric Hospital, Khartoum, Sudan.
Haemoglobin phenotype of patients (HbSS) and healthy controls
(HbAA) was conﬁrmed by cellulose acetate electrophoresis. The patients
were on regular folate supplement, before and after enrolment. The exclu-
sion criteria were: other chronic diseases and receiving blood transfusion
in the previous four-months. The group on omega-3 fatty acid received,
according to age, a daily dosage of 500–750 mg capsules containing
277.8 mg DHA and 39.0 mg EPA. The placebo group received capsules
containing high oleic acid (41%) oil blend. Vitamin E (1.5 mg/capsule)
was added to both types of capsules to prevent fatty acid peroxidation.
SCD patients on hydroxyurea treatment were on dosage more than
20mg/kg/day. The three groups of patientswere on their respective treat-
ment for a minimum of one year.
Omega-3 fatty acid treated (n= 24), hydroxyurea treated (n= 18)
and placebo (untreated) group (n = 21) HbSS patients and healthy
(HbAA) controls (n=25)matched for age (5–17 years), gender, ethnic-
ity and socio-economic backgroundwere included in the study. The ex-
pression of adhesive molecules was studied in a subgroup of omega-3
treated (n = 10) and untreated (n = 10) matched for age (11–
17 years) and gender before and after intervention.
After an overnight fast and according to age that is less or above
11 years old, 5 ml or 15 ml of whole blood was taken from the patients
and controls in EDTA tubes under sterilized conditions.
The Research Board of the Faculty of Medicine, University of
Khartoum, Sudan, approved the study. In addition, approval has been
obtained from National Research Ethics Service, Southampton & South
West Hampshire Research Ethics Committee (A) UK (REC reference:
05/Q1702/48). Informed written consents were obtained from the
participants or their guardians.
2.2. Preparation of the samples
The whole blood (5ml) was fractionated into red blood cells (RBCs)
and plasma by cold centrifugation at 3000 rpm for 15min. The top plas-
ma layer was carefully syphoned off and transferred into another tube.
The buffy coat was removed and transferred to a new tube containing
0.5 of RNA later (Sigma, UK) for RNA stabilisation. The lower red cell
layer was washed three times with physiological saline (0.85% NaCl)
and centrifuged to remove traces of plasma and buffy coat. The resulting
plasma and RBC pellet were thoroughly ﬂushed under oxygen-free ni-
trogen and immediately stored at−80 °C until analysis.
10ml of whole bloodwas used to obtainmonocytes and granulocytes
through a sequence of centrifugation steps using histopaque-1077 (den-
sity 1.077 g/ml) and histopaque-1119 (density 1.119 g/ml) (Sigma-
Aldrich, UK). Firstly, 3 ml of histopaque-1119 was added to a 50 ml tubefollowed by 3 ml of histopaque-1077 to form two distinct phases. Conse-
quently, 5 ml of the collected whole blood was layered carefully over the
histopaque and centrifuged at 700 ×g for 50 min at 22 °C (room temper-
ature). Separation of plasma, mononuclear cells/platelets, granulocytes
and red blood cells was obtained. The top layer (plasma) was transferred
to cryotubes and stored at−80 °C. The mononuclear cells/platelets frac-
tion was transferred to a new tube and re-suspended in 10 ml 1× phos-
phate buffer saline (1× PBS) (Sigma-Aldrich, UK) and centrifuged at
250 ×g for 10 min at 22 °C. The supernatant (platelets) was transferred
to a new 15 ml tube, whereas the remaining pellet was re-suspended
with 10 ml 1× PBS and washed twice by centrifugation at 250 ×g for
10 min. Mononuclear cells and granulocytes were washed twice with
10 ml 1× PBS at 2000 ×g for 5 min and resuspended in 450 μl serum ob-
tained from the same blood sample and 50 μl dimethyl sulfoxide (DMSO).
Red blood cells werewashed three timeswith normal saline (0.85%NaCl)
and centrifuged at 3000 rpm to remove traces of plasma and buffy coat.
The resulting plasma andRBCwere stored at−80 °C,whilstmononuclear
cells and granulocytes were stored in liquid nitrogen, until the analysis.
2.3. Haematological parameters
Before sample processing, Hb concentration, white blood cell
count (WBC) and platelet count were obtained by using an automat-
ed haematology analyser Sysmex KX-21N (Sysmex Corporation,
Kobe, Japan).
2.4. Analysis of red blood cell fatty acids
Total lipids were extracted by the method of Folch et al. (1957); the
detailed methodology was desecrated in our previous publication [14].
2.5. C-reactive protein (CRP) assay
C-reactive protein was assayed by using commercially available
enzyme-linked immunosorbent i-Chroma hsCRP test kits and an
i-CHROMA reader (Boditech, Korea).
2.6. Measurements of plasma tumour necrosis factor-α (TNF-α) and
interleukin-10 (IL-10)
Commercially available enzyme-linked immunosorbent assay (ELISA)
kits were used to determine TNF-α and IL-10 plasma concentration
(Pierce Biotechnology, Rockford, USA). All samples were analysed simul-
taneously using the same kits under the same analytical conditions.
2.7. Assessing β2-integrin CD11b/C18 (CD-11b) and L-selectin (CD62L)
expression in granulocytes and monocytes
Mononuclear cells and granulocytes were quickly defrosted at 37 °C.
200 μl of each defrosted sample was washed in 10 ml 1× PBS by centri-
fugation at 400 ×g for 5 min. The supernatant was discarded, and the
pellet was suspended in 1 ml 1× PBS/BSA 2 mg/ml (Sigma-Aldrich Co.
UK., A7906). 50 μl of cell suspension was incubated on a shaker with
10 μl (used as supplied) of anti-human-CD11b ﬂuorescein isothiocya-
nate (FITC) conjugated antibody, anti-human-CD62L-FITC, or mouse
anti-IgG, at 4 °C for one hour in the dark. Cells were also incubated
with no antibody at the same conditions, and used as negative control.
After incubation, cells were washed three times in 1.5 ml 1× PBS, by
centrifugation at 150 ×g for 5 min. Cell pellet was resuspended in
200 μl 1× PBS, and used for ﬂow cytometry analysis.
In order to standardise the positioning of monocytes, micro beads
conjugated to anti-Human-CD14 antibody were used for monocyte
puriﬁcation (Miltenyi Biotec GmbH, Germany). 107 total mononuclear
cells counted by microscope visualization using a counting chamber
were suspended in 80 μl of incubation buffer (0.5% BSA, 2 mM EDTA
in 1× PBS pH 7.2), and incubated with CD14 micro beads for 30 min
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times in incubation buffer by centrifugation at 300 ×g for 10 min. Cells
were resuspended in 500 μl of incubation buffer. Cells bound to CD14
micro beads were sequestered by the use of a column placed in a mag-
netic ﬁeld separator (Miltenyi Biotec GmbH, Germany). Cells were elut-
ed by washing the column with 1 ml of incubation buffer. Cells were
precipitated at 300 ×g, diluted in 1× PBS/BSA 2 mg/ml, and labelled
with anti-human-CD11b FITC conjugated anti-bodies. The ﬂuorescent
signal from the puriﬁed monocytes was compared to the same non-pu-
riﬁed sample.
Samples were loaded into 96-well plates in duplicates, and expres-
sions of CD11b and CD62L were measured by ﬂow cytometry using
the GUAVA PCA-96 ﬂow cytometer and GUAVA express plus software
(Guava technologies, UK). An optical emission ﬁlter for 580–583 nm
was used to detect FITC ﬂuorescence. Over 5000 cells were submitted
to analysis at each trial. Unlabelled cells and IgG labelled cells were
used as the negative control for non-speciﬁc ﬂow cytometry back-
ground. Monocytes and granulocytes cells were gated carefully based
on forward scatter and side scatter. We could not measure expression
of CD62L inmonocytes becausewedid not have enough samples to con-
duct the analysis.
2.8. RNA isolation and Reverse Transcription-Polymerase Chain Reaction
(PCR)
RNA was isolated from peripheral blood cells using RNAqueous Kit
according to the manufacturer's instructions (Ambion). RNA integrity
was checked by using 2% agarose gel electrophoresis. First strand
cDNA synthesis was performed using 1 μL total RNA and 300 ng/μL
random primers and SuperScript III Reverse Transcriptase (Life Tech-
nologies) as per manufacturer's instructions. The resultant cDNA stored
at−20 °C.
2.9. Quantitative Real-time Polymerase Chain Reaction
Real-time quantitative PCR of the cDNA template was performed in
an ABI Prism 7000 SDS (Applied Biosystems) run by software SDS-2.3.
The PCR reaction contained 4 μL of cDNA, 20 μL reaction mix (Rob mix,
ABI). The PCR cycling conditions were: 95 °C (15 s), 58 °C (20 s), 72 °C
(25 s) for 35 cycles. Results were calculated as expression of the target
gene (NF-κB) relative to expression of the reference gene (GAPDH).
2.10. Data analysis
The data were described bymean± SD or median and interquartile
rage (IQR) as pertinent. The three groups were compared for NF-κB
gene expression, TNF-α and CRP level by using one-way analysis of var-
iance (ANOVA).When statistical differences were indicated, Tamhane's
T2 pairwise multiple comparison post-hoc tests were performed. Non-
parametric test related-sample Wilcoxon signed ranks was applied to
explore differences in fatty acids, haematological proﬁle, TNF-α, IL-10
and adhesive molecule levels before and after intervention. Independent
sampleMann–WhitneyU test was used to test the effect of supplementa-
tion on fatty acid composition and adhesive molecules between the
groups. The statistical signiﬁcance was assumed at a p-value of less
than 0.05. The statistical software, SPSS for Windows, Version 19
(SPSS Ltd., Surrey, UK) was used to analyse the data.
3. Results
3.1. Fatty acid composition of red blood cell phosphatidyl ethanolamine
(PE) and choline (PC)
The fatty acid compositions of red blood cells PE and PC at baseline
and after one year of supplementationwith n−3 treated and untreated
(placebo) groups were included in Table 1. The fatty acid proﬁle of then−3 treated and untreated groups was comparable at base-line
(p N 0.05). In n−3 treated group, DHA and EPA increased three-fold
in red cell choline (PC) and ethanolamine (PE) phosphoglycerides
compared with the baseline (p b 0.001), whereas arachidonic acid (AA)
and total n−6 FAs were signiﬁcantly reduced in PE and PC (p b 0.001).
Intervention had no effect on PE fatty acid proﬁle after one year of sup-
plementation (p N 0.05) in n−3 untreated. However, signiﬁcant increase
in total n−6 and decrease in EPA of PC phosphoglyceride were detected
in n−3untreated group after one year of supplementation in comparison
to baseline.
3.2. Haematological parameters
Supplementation with n−3 and placebo increased Hb concentration
(p b 0.001). In contrast to the placebo group, n−3 supplements caused
signiﬁcant reduction on total white blood cells (TWBC) (P b 0.05). Both
n−3 treated and untreated groups, intervention showed no effect on
platelet count, Table 1.
3.3. Effect of n−3 supplementation on plasma C-reactive protein levels
(CRP)
Both treated and untreated groups of patients had higher con-
centrations of C-reactive protein compared with their healthy con-
trols (p b 0.001). There was no signiﬁcant difference in plasma CRP
concentrations between the supplemented and un-supplemented
patients (p N 0.05), Fig. 1.
3.4. Plasma levels of tumour necrosis factor-α (TNF-α) in hydroxyurea
(HU) treated and untreated group
The HbSS treated with hydroxyurea had a signiﬁcantly higher level
(p b 0.05) of TNF-α in comparison to the untreated group (Median =
41.7 (IQR = 24.4) pg/ml vs Median = 14.7 (IQR = 19.6) pg/ml) and
n−3 treated group (Median = 41.7 (IQR = 24.4) pg/ml vs Median =
15.8 (IQR = 8.8) pg/ml), Fig. 2.
3.5. Plasma levels of tumour necrosis factor-α (TNF-α) and interleukin-10
(IL-10) in n−3 treated, HU treated and untreated groups
Supplementationwith n−3 fatty acids had no effect on plasma TNF-α
(18.6 ± 12.8 vs 17.8 ± 9.1) (p N 0.05, Fig. 3a) and IL-10 (11.0 ± 4.3 vs
11.3 ± 5.8) compared to baseline levels (p N 0.05), Fig. 3b.
3.6. Expression of β2-integrin CD11b/C18 (CD-11b) in monocytes at
baseline
The level of adhesive molecules of placebo and active group were
comparable at baseline (p N 0.05), Fig. 4a and b.
After one year of supplementation with n−3, CD11b expression in
monocytes were signiﬁcantly lower compared to placebo and baseline
(P b 0.05), Figs. 4a and 5, respectively.
3.7. Expression ofβ2-integrin CD11b/C18 (CD-11b) and L-selectin (CD62L)
in granulocytes
The level of adhesive molecules of placebo and active group were
comparable at baseline (p N 0.05). Supplementationwith n−3 or place-
bo caused no signiﬁcant effect on CD11b and CD62L expression in
granulocytes (p N 0.05), Figs. 4b and 5.
3.8. Effect of omega-3 fatty acids and HU treatments on gene expression of
white blood cell NF-κB gene
Treatment with n−3 fatty acid resulted in a signiﬁcant reduction in
NF-κB gene relative fold gene expression in comparison to n−3
Table 1
Fatty acid composition of red blood cell phosphatidyl ethanolamine (PE) and choline (PC) and blood cell count at baseline and the end of one year intervention period.
n−3 treated, n = 19 Untreated (placebo group), n = 18
Measure Baseline One year Baseline One year
Fatty acids-PE
C18:2n−6 5.2 ± 0.8 5.2 ± 0.6 4.6 ± 0.6 5.0 ± 0.8
C20:4n−6 24.1 ± 1.2 22.2 ± 1.9⁎⁎⁎ 23.9 ± 1.4 24.5 ± 0.7
C22:4n−6 10.7 ± 1.2 7.2 ± 2.3⁎⁎⁎ 10.3 ± 0.3 10.2 ± 0.2
Total n−6 44.5 ± 1.2 36.9 ± 3.7⁎⁎⁎ 43.3 ± 1.2 43.7 ± 1.5
C20:5n−3 0.1 ± 0.04 0.3 ± 0.2⁎⁎⁎ 0.1 ± 0.03 0.1 ± 0.02
C22:5n−3 1.7 ± 0.3 1.4 ± 0.2⁎⁎⁎ 1.7 ± 0.3 1.6 ± 0.1
C22:6n−3 2.5 ± 0.7 8.8 ± 2.8⁎⁎⁎ 2.8 ± 9.4 2.5 ± 0.2
Total n−3 4.4 ± 0.9 10.6 ± 3.2⁎⁎⁎ 4.7 ± 0.4 4.2 ± 0.2
Fatty acids-PC
C18:2n−6 15.7 ± 2.3 18.1 ± 2.18⁎⁎⁎ 17.5 ± 2.5 19.2 ± 3.5
C20:4n−6 9.9 ± 1.0 7.9 ± 1.2⁎⁎⁎ 9.6 ± 0.4 8.8 ± 1.3
C22:4n−6 1.1 ± 0.2 0.6 ± 0.2⁎⁎⁎ 0.82 ± 0.05 0.6 ± 0.2⁎
Total n−6 29.5 ± 1.9 28.8 ± 2.7⁎ 30.6 ± 2.6 32.1 ± 2.8⁎
C20:5n−3 0.1 ± 0.04 0.24 ± 0.1⁎⁎⁎ 0.08 ± 0.05 0.04 ± .01⁎
C22:5n−3 0.3 ± 0.06 0.2 ± 0.1⁎⁎⁎ 0.3 ± 0.03 0.2 ± 0.08
C22:6n−3 0.7 ± 0.2 2.6 ± 0.9⁎⁎⁎ 0.7 ± 0.2 0.6 ± 0.3
Total n−3 1.2 ± 0.3 3.1 ± 1.1⁎⁎⁎ 1.2 ± 0.2 0.8 ± 0.3
Blood cell count
Hb g/l 64.5 ± 7.5 76.2 ± 6.8⁎⁎⁎ 67.4 ± 7.6 76.3 ± 11.3⁎⁎⁎
TWBC⁎103 15.3 ± 3.5 14.1 ± 2.8⁎ 13.2 ± 3.8 14.2 ± 4.3
PLTs⁎103 524.3 ± 141.4 487.6 ± 141.4 509.6 ± 232.9 484.5 ± 217.5
⁎ P b 0.05.
⁎⁎⁎ P b 0.001.
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showed no signiﬁcant difference when compared with untreated
group (p N 0.05) or omega-3 treated group (p N 0.05), Fig. 6.
4. Discussion
The anti-inﬂammatory effect of n−3 fatty acids is well documented
[24]. However, to the best of our knowledge, no study investigated the
effect of fatty acid supplementation on genetic and molecular markers
of inﬂammation in patients with sickle cell disease. Findings of this
study provide evidence that the observed beneﬁcial effects of n−3
fatty acid supplementation on patients with SCD could be partially
due to amelioration of chronic inﬂammation and increased blood cell
adhesion, the major causative factors of vaso-occlusion and complica-
tions characterizing the disease [25,26].0
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Fig. 1. C-reactive protein (CRP) concentration of HbSS patients n−3 treated, untreated
and healthy controls.The SCD patients and healthy who participated in this study were
from common ethnic and socio-economic backgrounds. The patients
were under regular management protocols and similar quality of care.
Moreover, baseline and one-year samples were collected at the same
season during the year. Supplementation with n−3 fatty acids resulted
inmore than twofold increase in EPA andDHA both in PE and PC. On the
other hand, fatty acids of the placebo group remained comparatively
constant apart from slight increase in total n−6 and decrease in EPA
of PC phosphoglyceride. Therefore it is unlikely to account the observed
results to factor(s) other than n−3 intervention or treatment with
hydroxyurea.
Total white blood count and CRP are known markers of systemic
global inﬂammatory activity. Consistent with the previous studies,
sickle cell patients have elevated baseline values of TWBC and CRP
[27,28]. These results provide additional evidence that SCD is a disease
with an important inﬂammatory component [1].
The observed decrease in TWBC owing to n−3 fatty acids supple-
mentation is constituent with ﬁndings obtained from conditions other
than SCD [29–31] and patients with SCD [16]. It is tenable; this0
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Fig. 2. Tumour necrosis factor-α (TNF-α) concentration of SCD patients treatedwith n−3
fatty acids or hydroxyurea and untreated controls.
Fig. 3. Plasma TNF-α concentrations (a) and IL-10 concentrations (b) of patients with n−3 fatty acids before and after one year of supplementation with n−3 fatty acid.
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ﬂammatory state [32,33] or diminished haemopoietic activity of the
bone marrow [34]. On the other hand, treatment with n−3 fatty acids
resulted in lower but not signiﬁcant levels of CRP or platelet count com-
pared to untreated patients. This ﬁnding is consistent with results re-
ported from studies on healthy adults [35], patients with chronic non-
autoimmune disease [36] and SCDpatients [37]. It is possible that a larg-
er sample size is needed to elucidate the effect of supplementation on
variables of huge inter-individual variations such as platelet count.Fig. 4.Monocyte integrins CD11b/C18 (CD-11b) at baseline and after one year intervention (F
intervention (Fig. 4b).TNF-α is a cytokine with a wide variety of actions that include acti-
vation of leukocytes, synthesis of acute phase proteins and the expres-
sion of adhesion molecules. Studies on the effect of HU treatment on
plasma TNF-α level yielded controversial results [38,39]. In this study,
HU treated patients had a high level of TNF-α. Considering the fact
that patients assigned to HU are those with a relatively severe type of
disease [40], the observed high levels of TNF-α could be a mere reﬂec-
tion of the well-known heterogeneous biological effects of HU treat-
ment in SCD [41].ig. 4a) and granulocyte integrins CD11b/CD18 (CD-11b) at baseline and after one year of
Fig. 5. The effect of n−3 fatty acid supplementation onmonocyte and granulocyte CD11 β2-integrin CD11b/C18 (CD-11b) and granulocyte selectin (CD62L) before and after intervention.
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mellitus [42,43], rheumatoid arthritis [44,45] and Crohn's disease [46],
supplementation with n−3 fatty acids showed no signiﬁcant change
on plasma levels of TNF-α or IL-10 [47]. Conversely, some studies that
measured the effect of supplementation on cytokine production by
monocytes [12,13] or local rather than systemic levels of cytokines
showed signiﬁcant effects [48]. This discrepancy between the systemic
and cell or tissue-speciﬁc levels is intriguing. Though, it gives some indi-
cation that systemic plasma cytokine levels are not sensitive enough to
reﬂect the tissue-speciﬁc immunological response to supplementation
with n−3 fatty acids [47]. Moreover, as previously suggested [11],
very high dose of n−3 fatty acidsmight be necessary to achieve detect-
able systemic anti-inﬂammatory response.
It has been shown that the adhesivemolecules involved in increased
adhesiveness of granulocytes andmonocytes and leukocytes interaction
with endothelial cells are the cytokine-induced L-and P-selectin (CD-
62L), β2-integrin CD11b/C18 (CD-11b) and LFA-1 (CD11a/CD18)
[49–52]. L-selectin (CD62L) facilitates rolling and temporary arrest of
circulating leukocytes on endothelium surface [53], whereas β2-
integrin (CD11b) is involved in subsequent stable adhesion [54,55].
Therefore, therapeutic approaches to reduce expression of CD62L and
CD11B have been important strategies to prevent vaso-occlusion
in sickle cell disease [50]. In vitro [56,57] and in vivo [13] studies in con-
ditions other than SCD have revealed that supplementation with n−3
resulted in signiﬁcant reduction in blood cell adhesive molecules. Inter-
estingly, we observed a signiﬁcant reduction of adhesive molecules in
monocytes in the group supplemented with n−3 fatty acids, the ﬁnd-
ing which denotes improvement in SCD-associated chronic inﬂamma-
tory state.
Experimental studies [10], and pilot clinical trials on patients with
disease have shown that NF-κB inhibition is associated with signiﬁcant-
ly reduced leukocyte adhesion and improved microvascular blood ﬂow
[7]. Strikingly, in the current study supplementation with n−3 fatty
acids, but not hydroxyurea, resulted in signiﬁcant reduction in white
blood cells' NF-κB gene expression in the patients with SCD. This resultR
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Fig. 6. Relative fold difference (RFD) of NF-κB gene expression of n−3 treated and n−3
not-treated and hydroxyurea treated HbSS sickle cell patients.is in line with whole genome gene expression studies in adults supple-
mented with n−3 fatty acids [58,59]. Knowing that NF-κB pathway
mediates oxidative stress response [60], the observed reduction in NF-
κB gene expression could be a reﬂection to the observed improvements
in the patients' oxidative stress status after supplementation with n−3
fatty acids [19]. The results of the present studymight also suggest path-
ways other thanNF-κB gene involved in hydroxyureawell-documented
anti-adhesive effects [9].
Chronic inﬂammation, intravascular haemolysis, imbalanced vascu-
lar nitric oxide (NO), oxidative stress are known factors that underlie
vasculapathy-related complications in SCD [61,62]. Among these com-
plications, pulmonary hypertension (PHT) and stroke stand out as the
most prevalent and devastating. Interestingly, SCD patients with PHT
have higher levels ofmarkers of endothelial activation, coagulation acti-
vation and other inﬂammatorymarkers than SCD patients without PHT.
Hence the clinical importance of the ﬁndings of this study, besides
supporting previous reports about the positive therapeutic effect of
n−3 fatty acids in SCD [16,18,19,37], that it suggests high DHA n−3
supplement as a potential intervention to prevent PHT, stroke and
other SCD vasculopathy-related complications.
One limitation of our study is that we did not measure the blood
cells' cytokine levels. Therefore, itwould be a justiﬁable analysis interest
to focus on the effect of supplementation on tissue- speciﬁc pro- and
anti-inﬂammatory cytokines, and fatty acids derived active metabolites
of the orthodox and novel pathways [63]. Based on the results of the
present study we might wish to suggest a relatively higher dosage of
n−3 for patients with SCD to achieve more potent systemic anti-
inﬂammatory effect.
In conclusion, the current study demonstrates that supplementation
with n−3 fatty acids mitigate some measures of inﬂammation and
blood cell adhesion in patients with sickle cell disease. The results of
this study provide some biological plausibility to n−3 therapeutic
effects on patients with sickle cell disease, and support its use as a safe
and effective treatment for acute and chronic complications of the
disease.
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